Product Description: Alvespimycin (17-DMAG) is a potent inhibitor of Hsp90, binding to Hsp90 with an EC50 of 62 ± 29 nM.
Applications: Cancer-programmed cell death
Formula: C32H48N4O8
Citations: Acs Biomater Sci Eng. 2021 Oct 12./Cell Death Dis. 2022 Jan 21;13(1):73./Exp Ther Med. February 10, 2022./Friedrich-Alexander University Erlangen-Nuremberg. 2016 Sep 14./NPJ Precis Oncol. 2023 May 18;7(1):44./Pharmacol Res. 2020 Jan;151:104512./Sci Rep. 2021 May 26;11(1):11057./Theranostics. 2020 Jul 9;10(18):8415-8429./Authorea. April 10, 2021./Biochim Biophys Acta Mol Cell Res. 2024 Mar 5:119703./bioRxiv. 2021 Jan 27./Br J Pharmacol. 2021 Nov;178(22):4485-4500./Front Pharmacol. 14 January 2022./Nat Commun. 2021 Jul 22;12(1):4457.
References: [1]Ge J, et al. Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90. J Med Chem. 2006 Jul 27;49(15):4606-15./[2]Hertlein E, et al. 17-DMAG targets the nuclear factor-kappaB family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibition. Blood. 2010 Jul 8;116(1):45-53./[3]Henke A, et al. Reduced Contractility and Motility of Prostatic Cancer-Associated Fibroblasts after Inhibition of Heat Shock Protein 90. Cancers (Basel). 2016 Aug 24;8(9). pii: E77.
CAS Number: 467214-20-6
Molecular Weight: 616.75
Compound Purity: 99.59
Research Area: Cancer
Solubility: DMSO : 100 mg/mL (ultrasonic)
Target: HSP
Deutsch
English
